Introduction
============

It has been demonstrated that inflammation serves important roles in the development, growth and/or invasion of various types of cancer ([@b1-ol-0-0-11462]--[@b3-ol-0-0-11462]). For example, *Helicobacter pylori* (*H. pylori*) infection causes chronic inflammation in the gastric mucosa and is subsequently involved in the development of gastric cancers (GCs) ([@b4-ol-0-0-11462],[@b5-ol-0-0-11462]), although the precise mechanism remains unclear. Proinflammatory cytokines function not only in the gastrointestinal immune system, but also in cell growth and/or apoptosis in the gastric mucosa, resulting in the development and progression of GCs ([@b6-ol-0-0-11462],[@b7-ol-0-0-11462]). Downstream of cytokine signaling, various activated transcription factors, such as signal transducer and activator of transcriptions (STATs), NF-κB and AP-1, serve a role in the regulation of target genes that are involved in gastric carcinogenesis ([@b7-ol-0-0-11462]). Among these cytokine-associated transcription factors, STAT3 has been highlighted in inflammation-associated carcinogenesis in various organs, such as lung, pancreas and liver ([@b8-ol-0-0-11462]--[@b12-ol-0-0-11462]). Notably, mice possessing STAT3 hyperactivation, which lack the negative feedback by SHP2/SOCS3 binding onto gp130, develop gastric tumors accompanied by chronic gastritis ([@b13-ol-0-0-11462],[@b14-ol-0-0-11462]); however, the clinical significance of overactivated STAT3 and its function in human gastric carcinogenesis remains to be clarified. STAT3 is constitutively activated in numerous types of cancer, for example lung and pancreatic cancer and hepatocellular carcinoma ([@b15-ol-0-0-11462]--[@b17-ol-0-0-11462]), and serves a role in cell proliferation, migration and in anti-apoptosis by activating target genes, including *cyclin D1*, matrix metalloproteases or *Bcl-xL* ([@b18-ol-0-0-11462],[@b19-ol-0-0-11462]). It has also been shown that Ki67 is a well-known marker to evaluate the ability of cell proliferation ([@b20-ol-0-0-11462]). Hence, the present study aimed to investigate the correlation between phosphorylated (p-)STAT3 and Ki67 expression levels in patients with early GC.

*H. pylori* infection over two decades causes a sequence of histological changes in the non-neoplastic gastric mucosa (non-NGM), referred to as Correa\'s hypothesis ([@b4-ol-0-0-11462],[@b5-ol-0-0-11462]), along with simultaneous accumulation of genetic and epigenetic alterations, for example microsatellite instability or *p53* and *E-cadherin* mutations ([@b21-ol-0-0-11462],[@b22-ol-0-0-11462]). Cytokine signaling activates cytokine receptor-associated Janus kinase (JAK) ([@b23-ol-0-0-11462],[@b24-ol-0-0-11462]), which in turn phosphorylates STAT3, rendering it functional ([@b23-ol-0-0-11462],[@b24-ol-0-0-11462]). On the other hand, *the suppressor of cytokine signaling 3* (*SOCS3*) can bind to cytokine receptors and JAK to inhibit JAK/STAT3 signaling, acting as a tumor suppressor in a negative feedback loop ([@b25-ol-0-0-11462],[@b26-ol-0-0-11462]). In this regard, alteration of *SOCS3* appears to be a crucial step of carcinogenesis in various organs, including the head and neck, pancreas, liver, blood and brain ([@b27-ol-0-0-11462]--[@b31-ol-0-0-11462]). The present study investigated *SOCS3* methylation and p-STAT3 expression levels in the non-NGM of patients with early GC in relation to non-NGM cell proliferative ability that may impact GC development.

Materials and methods
=====================

### Patients and biopsies

A total of fifty-one patients with early GC (39 male and 12 female; median age 72; age range 48--87) and 22 patients with gastritis without GC (12 males and 10 females; median age 64; age range 30--81) were enrolled into the present study between January 2011 and March 2013 at the Hyogo College of Medicine Hospital (Hyogo, Japan). Patients with early GC were diagnosed by previous endoscopic examination with biopsy at the Hyogo College of Medicine Hospital. The exclusion criteria were as follows: i) Patients with malignancy in other organs; ii) patients with an allergy to drugs used for *H. pylori* eradication; iii) patients regularly taking a nonsteroidal anti-inflammatory drug, including aspirin; iv) patients with a history of esophagectomy or gastrectomy; and v) patients who were determined by their physicians to be unqualified for any other reason, for example severe pneumonia. Biopsy specimens were routinely obtained from the non-NGM of all patients at the greater curvature of the mid corpus of the stomach (at least 3 cm far from the lesion), where biopsy was possible before and after treatment with endoscopic submucosal resection (ESD). All patients with early GC underwent ESD and were followed up using endoscopic examination 1 year later. Among them, 13 patients received *H. pylori* eradication after ESD treatment and biopsy specimens were obtained for a second time from the same location at the greater curvature of the stomach when undergoing follow-up endoscopic examinations 1 year after ESD. The severity of gastric atrophy was classified by endoscopic examination according to the criteria of Kimura and Takemoto, as reported previously ([@b32-ol-0-0-11462],[@b33-ol-0-0-11462]). The serum was isolated from blood samples from the patients before ESD treatment. The serum *H. pylori* immunoglobulin G (IgG) antibody titer was analyzed using an ELISA kit (E plate test; Eiken Chemical Co., Ltd.). Written informed consent was provided by all the patients and the present study was approved by The Ethics Committee of Hyogo College of Medicine.

### DNA extraction and bisulfite treatment

DNA was isolated from biopsy specimens using a QIAamp DNA Micro kit (Qiagen GmbH). The DNA (500 ng) was modified with sodium bisulfite using an EpiTect Bisulfite kit (Qiagen GmbH), as recommended in the manufacturer\'s protocol ([@b34-ol-0-0-11462]). Sodium bisulfite converts unmethylated cytosine to uracil, whereas methylated cytosines are resistant ([@b35-ol-0-0-11462]). DNA samples were subsequently purified using the Wizard DNA Clean-Up System (Promega Biotechnologies, Inc.) and precipitated in 16 µl water, as previously reported ([@b34-ol-0-0-11462]).

### Qualitative methylation-specific PCR (MSP) for SOCS3 gene

Bisulfite-treated genomic DNA was amplified using either methylated or unmethylated specific primer sets, using the sequences as follows: Methylated specific forward, 5′-TATATATTCGCGAGCGCGGTTT-3′, and reverse, 5′-CGCTGCGCCCAGATGTT-3′; unmethylated specific forward, 5′-TGTGGTGGTTGTTTATATATTTGTGAGTGTGGTT-3′, and reverse, 5′-CAACCAACAATAACCCACACTACACCCA-3′ ([@b36-ol-0-0-11462]). The amplifications were performed in a total reaction volume of 50 µl containing 20 pmol of each set of primers, 1.25 U EpiTaq HS DNA polymerase, PCR buffer with MgCl~2~ (both Takara Bio, Inc) and 0.3 mM each dNTP. The PCR was conducted as follows: Initial denaturation at 95°C for 5 min; 30 cycles at 98°C for 10 sec; 64°C for 30 sec; 72°C for 30 sec; final extension at 72°C for 7 min. The PCR products were electrophoresed using 2% agarose gel and then visualized using ethidium bromide staining under UV illumination.

### Immunohistochemistry

The biopsy specimens were fixed in 10% formalin solution at room temperature overnight and embedded in paraffin. Immunohistochemical staining for Ki67 and p-STAT3 was performed using an Envision kit (Dako; Agilent Technologies) as previously described ([@b37-ol-0-0-11462],[@b38-ol-0-0-11462]), using the primary antibodies anti-Ki67 antibody (1:50; cat no. IR626; Dako; Agilent Technologies) and anti-phospho-specific STAT3 (Tyr705) antibody (1:15; cat no. 9131; Cell Signaling Technology). In brief, 4-µm-thick sections were placed on slides, deparaffinized in xylene and rehydrated through a descending series of ethanol (100, 90, 80 and 70%). The slides were then placed in Dako REAL Target Retrieval Solution (Dako; Agilent Technologies) and treated by microwave heating (MI-77; Azumaya) at 400 W and 95°C for 10 min to facilitate antigen retrieval, followed by pretreatment with 0.3% H~2~O~2~ in methanol for 20 min at room temperature to quench endogenous peroxidase activity. The sections were then washed 3 times by phosphate-buffered saline and followed by the treated with blocking buffer (Protein Block Serum-Free; Dako Agilent Technologies) for 30 min at room temperature. Thereafter, the sections were incubated with the primary antibodies for 60 min at room temperature, washed 3 times in phosphate-buffered saline and incubated with anti-mouse (ready to use; cat. no. K4001) or anti-rabbit IgG antibody (ready to use; cat. no. K4003) (both Dako; Agilent Technologies, Inc.) for 30 min at room temperature and washed 3 times in phosphate-buffered saline. Finally, the sections were incubated in 3,3′-diaminobenzidine tetrahydrochloride with 0.05% hydrogen peroxide for 3 min at room temperature and then counterstained with Mayer\'s hematoxylin for 1 min at room temperature.

To evaluate the immunoreactivity of Ki67 and p-STAT3, 100 epithelial cells were counted in 5 different visual fields for each section under light microscope (magnification, ×400). The labeling index was calculated as the percentage of positive cells.

### Statistical analysis

All values were expressed as the mean ± standard error of the mean. The significance of differences between two unpaired groups was assessed using a Student\'s t-test or Mann-Whitney U-test. Clinicopathological parameters including sex, age, anti-*H. pylori* antibody, gastric atrophy and *SOCS3* methylation positivity, were assessed using χ^2^ analyses. The correlation between p-STAT3 and Ki67 labeling index was assessed using linear regression analysis. For multiple comparisons, the paired data before and after eradication were analyzed using two-way repeated measures ANOVA followed by Bonferroni\'s correction. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Association between the characteristics of patients and SOCS3 methylation in the non-NGM of patients with or without early GC

Representative electrophoresis gels of MSP products for *SOCS3* are shown in [Fig. 1](#f1-ol-0-0-11462){ref-type="fig"}. The clinical and endoscopic features of the patients with or without early GC are presented in [Table I](#tI-ol-0-0-11462){ref-type="table"}. A total of 17 out of the 51 patients with early GC (33.3%) had *SOCS3* methylation. Sex, age, anti-*H. pylori* antibody and gastric atrophy were not significantly associated with *SOCS3* methylation positivity in the non-NGM of patients with early GC. The positivity of *SOCS3* methylation in the non-NGM was significantly higher in patients with early GC compared with those without (P=0.020) ([Table I](#tI-ol-0-0-11462){ref-type="table"}). Parameters including age (P=0.0003), anti-*H. pylori* antibody (P=0.0001) and gastric atrophy (P=0.0005) were significantly different between patients with early GC and those without ([Table I](#tI-ol-0-0-11462){ref-type="table"}). Regarding anti-*H. pylori*-IgG level, 19/51 patients with early GC were negative; however, 14 (74%) of these 19 patients showed an open-type gastric atrophy. Overall, 6/51 early GC patients was negative for anti-*H. pylori* antibody due to past eradication therapy. *SOCS3* methylation was detected in 3/6 of these patients with early GC. *SOCS3* methylation positivity was detected in 4/10 (40%) patients with early GC with closed-type atrophy and in 13/41 (32%) of patients with open-type atrophy.

A total of 22 patients had chronic gastritis but no cancerous lesions. Among them, 15 patients were positive for both anti-*H. pylori* antibody and gastric atrophy and 2 (13.3%) were also positive for *SOCS3* methylation. A total of 5 patients were negative for both anti-*H. pylori* antibody and gastric atrophy and had no *SOCS3* methylation ([Table II](#tII-ol-0-0-11462){ref-type="table"}). The remaining two patients were negative for anti-*H. pylori* antibody after eradication but positive for gastric atrophy. These patients had no *SOCS3* methylation. When the 15 patients with anti-*H. pylori* antibody-positivity were compared with 5 patients with anti-*H. pylori* antibody negativity, the presence of gastric atrophy was significantly associated with *H. pylori* infection (P\<0.0001) ([Table II](#tII-ol-0-0-11462){ref-type="table"}).

The group of patients without early GC contained patients positive and negative for *H. pylori* infection. The 15 patients who were positive for both anti-*H. pylori* antibody were isolated, then gastric atrophy and the associations between characteristics of patients and *SOCS3* methylation in the non-NGM of patients with or without early gastric cancer were re-analyzed. Subsequently, age, gastric atrophy and the positivity of *SOCS3* methylation in the non-NGM was significantly higher in patients with early GC compared with that in patients without early GC (P=0.047, P=0.0002 and P=0.046, respectively; [Table III](#tIII-ol-0-0-11462){ref-type="table"}).

### Correlation between SOCS3 methylation and p-STAT3 and Ki67 expression levels in the non-NGM in patients with early GC

p-STAT3 immunoreactivity was observed in the nuclei of the non-neoplastic epithelial cells in the gastric mucosa ([Fig. 2A](#f2-ol-0-0-11462){ref-type="fig"}). The p-STAT3 labeling index in the non-NGM was significantly higher in early GC patients with SOCS3 methylation compared with those without (P\<0.001; [Fig. 2B](#f2-ol-0-0-11462){ref-type="fig"}). Ki67 immunoreactivity (as a cell proliferation marker) was also observed in the nuclei of the non-neoplastic epithelial cells in the gastric mucosa ([Fig. 2C](#f2-ol-0-0-11462){ref-type="fig"}). The Ki67 labeling index in the non-NGM was significantly higher in patients with early GC with *SOCS3* methylation compared with those without (P\<0.001; [Fig. 2D](#f2-ol-0-0-11462){ref-type="fig"}).

It is known that activated STAT3 plays a pivotal role in cell proliferation ([@b11-ol-0-0-11462],[@b12-ol-0-0-11462]). Therefore, the correlation between p-STAT3 and Ki67 expression levels was investigated in the non-NGM of patients with early GC. The labeling index of Ki67 was positively correlated with that of p-STAT3 (r=0.414; P=0.0025; [Fig. 3](#f3-ol-0-0-11462){ref-type="fig"}).

### Effect of H. pylori eradication on SOCS3 methylation and p-STAT3/Ki67 expression in the non-NGM in patients with early GC

A total of 13 patients were investigated who received *H. pylori* eradication therapy after ESD and in whom gastric biopsy sampling had been performed prior to and one year following eradication. A total of 4 patients were positive for *SOCS3* methylation, whereas 9 were negative ([Fig. 4](#f4-ol-0-0-11462){ref-type="fig"}); although the small number examined was a limitation in this study.

Before *H. pylori* eradication, the p-STAT3 labeling index in the non-NGM was significantly higher in the *SOCS3* methylation-positive group (33.6±4.9) than in negative group (17.7±3.6) (P\<0.05). After eradication, the p-STAT3 labeling index was significantly reduced in the *SOCS3* methylation-negative group (9.6±2.1) (P\<0.05) but remained unchanged in the *SOCS3* methylation-positive group. The p-STAT3 labeling index remained significantly higher in the *SOCS3* methylation-positive group (25.8±4.7) compared with that in the negative group ([Fig. 4A](#f4-ol-0-0-11462){ref-type="fig"}).

Ki67 expression levels were also investigated in the aforementioned 13 patients. Before *H. pylori* eradication, the Ki67 labeling index in the non-NGM was significantly higher in the *SOCS3* methylation-positive group (23.0±3.7) compared with that in the negative group (10.3±2.1) (P\<0.05). This difference was sustained even after eradication (P\<0.05). In the *SOCS3* methylation-negative group, the Ki67 labeling index was significantly reduced by eradication treatment (4.5±1.2), whereas it was not significantly changed after eradication in the *SOCS3* methylation-positive group (32.7±7.0) ([Fig. 4B](#f4-ol-0-0-11462){ref-type="fig"}).

Discussion
==========

*SOCS3* methylation frequently occurs in various epithelial and non-epithelial malignancies, including head and neck squamous cell carcinoma, pancreatic cancer, hepatocellular carcinoma, multiple myeloma and glioma ([@b27-ol-0-0-11462]--[@b31-ol-0-0-11462]). *SOCS3* methylation is also detectable in various inflammation-associated gastroenterological malignancies, including hepatocellular carcinoma ([@b39-ol-0-0-11462]), Barrett\'s adenocarcinoma ([@b40-ol-0-0-11462]) and ulcerative colitis-associated types of colorectal cancer ([@b41-ol-0-0-11462]), suggesting the involvement of *SOCS3* methylation in different types of inflammatory gastric cancer. In the present study, the status of *SOCS3* methylation in the non-NGM, where GC arises, was investigated, and it was revealed that *SOCS3* methylation was detectable in patients with early GC and in patients with non-GC gastritis. It is still unclear whether *SOCS3* methylation is specific for *H. pylori*-related gastritis however, it is worth noting that the patients with gastritis with positive *SOCS3* methylation had also been infected with *H. pylori*. The occurrence of *SOCS3* methylation in non-NGM of patients with early GC was significantly higher compared with that in patients without GC (P=0.020). However, as the group without GC included *H. pylori* positive- and negative-patients, *H. pylori*-positive patients without early GC and early GC patients were further compared. As a result, the occurrence of *SOCS3* methylation in non-NGM was still higher in patients with early GC compared with patients without early GC ([Table III](#tIII-ol-0-0-11462){ref-type="table"}), suggesting that *SOCS3* methylation may occur in the development of *H. pylori*-induced gastritis-carcinoma. However, as a limitation of the present study, the number of patients with *H. pylori*-infected gastritis was small. Therefore, the aforementioned hypothesis requires further investigation. In addition, it is well-known that the frequency of methylation increases with age ([@b42-ol-0-0-11462],[@b43-ol-0-0-11462]) and the grade of atrophy and age was greater in patients with early GC compared with those without ([Table I](#tI-ol-0-0-11462){ref-type="table"}). Thus, the aging factor and its associated gastric atrophy may affect the frequency of *SOCS3* methylation when comparing the patients with early GC and those without. However, when the patients with early GC where analyzed alone, the occurrence of *SOCS3* methylation in non-NGM was not affected by age or gastric atrophy. This may suggest that *SOCS3* methylation in the non-NGM may not always occur in older patients with high-grade gastric atrophy.

SOCS3 is a negative regulator of JAK/STAT signaling and may act as a tumor suppressor ([@b25-ol-0-0-11462],[@b26-ol-0-0-11462]). Thus, dysfunction of SOCS3 resulting from methylation could lead to continuous activation of STAT3 signaling and *SOCS3* methylation has been reported to be associated with activation of STAT3 phosphorylation in some types of carcinogenesis, such as pancreatic cancer, ulcerative colitis-associated cancer and cholangiocarcinoma ([@b31-ol-0-0-11462],[@b41-ol-0-0-11462],[@b44-ol-0-0-11462]). In the present study, the association between *SOCS3* methylation status and p-STAT3 expression levels were investigated in non-neoplastic epithelial cells in the gastric mucosa of patients with early GC. It was revealed that p-STAT3 expression was higher in patients positive for *SOCS3* methylation. Activated STAT3 serves a role in cell proliferation in carcinogenesis ([@b45-ol-0-0-11462],[@b46-ol-0-0-11462]) and therefore the association between *SOCS3* methylation status and Ki67 expression levels were also investigated. The results from the present study revealed that Ki67 expression levels were enhanced in patients with early GC positive for *SOCS3* methylation, consistent with a previous study which revealed that enhanced Ki67 expression was associated with the suppression of SOCS3 expression levels in hepatocellular carcinoma ([@b47-ol-0-0-11462]). Moreover, the expression levels of p-STAT3 and Ki67 showed a positive association in the non-NGM of patients with early GC in the present study, similar to a previous report in which p-STAT3 expression and Ki67 expression levels were associated in glioblastomas ([@b48-ol-0-0-11462]). The findings of the present study suggest that the activated STAT3 signaling associated with *SOCS3* methylation may accelerate the proliferative ability of gastric epithelial cells in individuals at risk of developing GC lesions. It is of concern that the expression levels of p-STAT3 and Ki67 were compared irrespective of *H. pylori* status using a serum anti-*H. pylori* test, especially as anti-*H. pylori*-IgG expression levels are often negative in patients with severe atrophic stomach mucosa and/or widely spread intestinal metaplasia ([@b49-ol-0-0-11462],[@b50-ol-0-0-11462]). Indeed, in regardless of eradication, 19/51 patients with early GC were negative for anti-*H. pylori*-IgG level in the present study and 74% of such patients showed an open-type gastric atrophy. It was a limitation in the present study that *H. pylori* status was determined using anti-*H. pylori*-IgG expression levels. However, it is notable that *SOCS3* methylation often occurs in patients with open- and closed-type gastric atrophy, suggesting that *SOCS3* methylation may occur in an early phase of progression of gastric atrophy.

The effect of *H. pylori* eradication on p-STAT3 and Ki67 expression levels in the non-NGM of patients with early GC after ESD treatment were subsequently investigated. p-STAT3 expression levels were significantly reduced following eradication therapy in patients with early GC with negative *SOCS3* methylation, whereas no such effect was evident in patients with early GC with positive *SOCS3* methylation. Similarly, eradication therapy significantly reduced the expression levels of Ki67 in patients with early GC with negative *SOCS3* methylation, but not significantly different in those with *SOCS3* methylation. It has been suggested that genetic abnormalities, such as microsatellite instability or methylations ([@b51-ol-0-0-11462],[@b52-ol-0-0-11462]), that accumulate in the gastric mucosa during *H. pylori*-induced chronic gastritis are difficult to reverse using eradication therapy ([@b52-ol-0-0-11462]) and that GCs often occur in patients after successful *H. pylori* eradication ([@b53-ol-0-0-11462]). In the present study, early GC developed in 6 patients after eradication and *SOCS3* methylation was detected in 3 of these patients. It was also demonstrated that eradication had no effect on p-STAT3 and Ki67 expression levels in the non-NGM of patients with early GC with positive *SOCS3* methylation. The aforementioned findings from the present study and previous research suggest that the non-NGM retains a high propensity for cell proliferation in patients with early GC with positive *SOCS3* methylation. However, it is a limitation of the present study that the number of patients followed-up after eradication was small to divide the patients according to *SOCS3* methylation status. Thus, to verify the results in the present study, large scale studies, with a large number of patients during follow-up after eradication, will be required.

In summary, it has been demonstrated that *SOCS3* methylation *frequently occurs in the* non-NGM of patients with early GC. Moreover, it was *shown that H. pylori eradication does not affect p-STAT3 or Ki67 expression levels in the* non-NGM of patients with early GC with positive *SOCS3* methylation. The results from the preset study suggest that *SOCS3* methylation is associated with continuous p-STAT3 overexpression and enhancement of epithelial cell proliferation in the non-NGM of patients with early GC, serving a role in the development of GC. However, the present study had several limitations including the lack of quantitative evaluation of *SOCS3* methylation and the suitability of sampling of biopsy specimen. For instance, if biopsy specimens had been collected near the cancerous lesions, the detection rate of *SOCS3* methylation might be increased. In addition, quantitative evaluation of *SOCS3* methylation might clarify more significant correlations among patients\' characteristics, p-STAT3 and Ki67 expression levels in patients with early GC. Further studies are required to investigate whether *SOCS3* methylation could be a predictive marker for the development of first and/or metachronous GC in a future large-scale studies.
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![Methylation specific PCR analysis of the suppressor of cytokine signaling 3 promoter region in the non-neoplastic gastric mucosa of patients without (A) or with (B) early GC. Representative cases are presented. Black arrows indicating the position of PCR products expected. U, unmethylated; M, methylated; GC, gastric cancer.](ol-19-05-3542-g00){#f1-ol-0-0-11462}

![Immunostaining of p-STAT3 and Ki67 in the non-NGM of patients with early GC. (A) Immunohistochemical localization of p-STAT3 in the non-NGM of patients with early GC positive and negative for *SOCS3* methylation. (B) Comparison of p-STAT3 labeling index between negative and positive groups for *SOCS3* methylation. (C) Immunohistochemical localization of Ki67 in non-NGM of patients with early GC positive and negative for *SOCS3* methylation. (D) Comparison of Ki67 labeling index between negative and positive groups for *SOCS3* methylation. p-, phosphorylated; STAT3, signal transducer and activator of transcription 3; non-NGM, non-neoplastic gastric mucosa; GC, gastric cancer; *SOCS3*, suppressor of cytokine signaling 3.](ol-19-05-3542-g01){#f2-ol-0-0-11462}

![Correlation between p-STAT3 and Ki67 labeling indices in the non-neoplastic gastric epithelium of patients with early gastric cancer. p-, phosphorylated; STAT3, signal transducer and activator of transcription 3.](ol-19-05-3542-g02){#f3-ol-0-0-11462}

![Effect of *H. pylori* eradication on (A) p-STAT3 and (B) Ki67 expression levels in the non-neoplastic gastric epithelium of patients with early GC, in relation to *SOCS3* methylation status. Bars represent the average. \*P\<0.05. NS, not significant; Era, eradication; p-, phosphorylated; STAT3, signal transducer and activator of transcription 3; *SOCS3*, suppressor of cytokine signaling 3; *H. pylori, Helicobacter pylori;* Era, eradication.](ol-19-05-3542-g03){#f4-ol-0-0-11462}

###### 

Characteristics of patients with (n=51) and without (n=22) early gastric cancer.

                                                                                      Without early GC    With early GC                            
  ----------------------------------------------------------------------------------- ------------------- --------------- ------------------- ---- ----------
  Sex, n (n; %)^[a](#tfn1-ol-0-0-11462){ref-type="table-fn"}^                                             NS                                  NS   NS
    Male                                                                              12 (0; 0.0)                           39 (12; 30.8)          
    Female                                                                              10 (2; 20.0)                      12 (5; 41.7)             
  Mean age ± SEM (range), years                                                       61.1±2.9 (30--81)   NS              71.1±1.2 (48--87)   NS     0.0003
    \<65 years, n (n; %)^[a](#tfn1-ol-0-0-11462){ref-type="table-fn"}^                11 (0; 0.0)                         13 (4; 30.8)             0.041
    ≥65 years, n (n; %)^[a](#tfn1-ol-0-0-11462){ref-type="table-fn"}^                   11 (2; 18.2)                        38 (13; 34.2)          
  Anti-*H. pylori* antibody, n (n; %)^[a](#tfn1-ol-0-0-11462){ref-type="table-fn"}^                       NS                                  NS     0.0001
    Negative                                                                            5 (0; 0.0)                        19 (6; 31.6)             
    Positive                                                                            15 (2; 13.3)                      26 (8; 30.8)             
    Era-negative                                                                        2 (0; 0.0)                          6 (3; 50.0)            
  Gastric atrophy, n (n; %)^[a](#tfn1-ol-0-0-11462){ref-type="table-fn"}^                                 NS                                  NS     0.0005
    None                                                                                5 (0; 0.0)                        0 (0; 0.0)               
    Closed                                                                              7 (1; 14.3)                       10 (4; 40.0)             
    Open                                                                                10 (1; 10.0)                        41 (13; 31.7)          
  *SOCS3* methylation positive, n (%)                                                                                                              0.020
    Positive                                                                          2 (9.1)                             17 (33.3)                
    Negative                                                                          20 (90.9)                           34 (66.7)                

The number of patients positive for SOCS3 methylation and the percentage. GC, gastric cancer; NS, not significant; Era-negative, negative for Anti-*H. pylori* antibody post eradication therapy; SOCS3, suppressor of cytokine signaling 3; *H. pylori, Helicobacter pylori;* SEM, standard error of the mean.

###### 

Characteristics in patients without early gastric cancer, with or without *H. pylori* infection.

  Characteristic                                                                   *H. pylori*-negative (n=5)   *H. pylori*-positive (n=15)   P-value
  -------------------------------------------------------------------------------- ---------------------------- ----------------------------- ----------
  Sex, n (n; %)^[a](#tfn2-ol-0-0-11462){ref-type="table-fn"}^                                                                                 NS
    Male                                                                           2 (0; 0.0)                   10 (0; 0.0)                   
    Female                                                                         3 (0; 0.0)                     5 (2; 40.0)                 
  Mean age ± SEM (range), years                                                    66.8±2.3 (62--74)            58.1±3.9 (30--81)             NS
    \<65 years, n (n; %)^[a](#tfn2-ol-0-0-11462){ref-type="table-fn"}^               2 (0; 0.0%)                  8 (0; 0.0)                  NS
    ≥65 years, n (n; %)^[a](#tfn2-ol-0-0-11462){ref-type="table-fn"}^              3 (0; 0%)                      7 (2; 28.6)                 
  Gastric atrophy, years, n (n; %)^[a](#tfn2-ol-0-0-11462){ref-type="table-fn"}^                                                              \<0.0001
    None                                                                           5 (0; 0.0)                     0 (0; 0.0)                  
    Closed                                                                         0 (0; 0.0)                     7 (1; 14.3)                 
    Open                                                                           0 (0; 0.0)                     8 (1; 12.5)                 
  *SOCS3* methylation positive                                                     0 (0.0)                      2 (13.3)                      NS

The number of patients positive for SOCS3 methylation and the percentage. GC, gastric cancer; NS, not significant; *H. pylori, Helicobacter pylori;* SOCS3, suppressor of cytokine signaling 3; SEM, standard error of the mean.

###### 

Characteristics in patients with early gastric cancer with *H. pylori* infection and patients with early gastric cancer without *H. pylori* infection.

  Characteristics                                                           Without early GC *H. pylori*-positive, n=15   With early GC, n=51   P-value, with vs. without
  ------------------------------------------------------------------------- --------------------------------------------- --------------------- --------------------------------------------------------
  Sex, n (n; %)^[a](#tfn3-ol-0-0-11462){ref-type="table-fn"}^                                                                                   NS
    Male                                                                      10 (0; 0.0%)                                  39 (12; 30.8)       
    Female                                                                    5 (2; 40.0%)                                12 (5; 41.7)          
  Mean age ± SEM (range), years                                             58.1±3.9 (30--81)                             71.1±1.2 (48--87)     0.0002
    \<65 years, n (n; %)^[a](#tfn3-ol-0-0-11462){ref-type="table-fn"}^      8 (0; 0.0)                                    13 (4; 30.8)          0.047^[b](#tfn4-ol-0-0-11462){ref-type="table-fn"}^
    ≥65 years, n (n; %)^[a](#tfn3-ol-0-0-11462){ref-type="table-fn"}^         7 (2; 28.6)                                   38 (13; 34.2)       
  Gastric atrophy, n (n; %)^[a](#tfn3-ol-0-0-11462){ref-type="table-fn"}^                                                                         0.0002^[b](#tfn4-ol-0-0-11462){ref-type="table-fn"}^
    None                                                                    0 (0; 0.0)                                    0 (0; 0.0)            
    Closed                                                                    7 (1; 14.3)                                 10 (4; 40.0)          
    Open                                                                      8 (1; 12.5)                                   41 (13; 31.7)       
  *SOCS3* methylation positive                                              2 (13.3)                                      17 (33.3)             0.046^[b](#tfn4-ol-0-0-11462){ref-type="table-fn"}^

The number of patients positive for SOCS3 methylation and the percentage.

P-value analyzed by χ^2^ test. GC, gastric cancer; NS, not significant; *H. pylori, Helicobacter pylori*; *SOCS3*, suppressor of cytokine signaling 3; SEM, standard error of the mean.
